BioStar Capital closes Fund V at $130.3m
BioStar Capital, a strategic healthtech venture capital firm focused on cardiovascular disease, orthopaedics, and robotics, has closed its fifth fund at $130.3m, more than the combined amount raised by the firm’s three previous funds.